Insider Buying: Alumis (NASDAQ:ALMS) Director Purchases $6,999,988.00 in Stock

Alumis Inc. (NASDAQ:ALMS) Director James Tananbaum acquired 411,764 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the transaction, the director owned 5,702,536 shares in the company, valued at $96,943,112. The trade was a 7.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Alumis Stock Performance

Shares of ALMS opened at $24.34 on Thursday. The stock has a market capitalization of $2.54 billion, a P/E ratio of -6.01 and a beta of -2.09. Alumis Inc. has a 1 year low of $2.76 and a 1 year high of $24.83. The company’s fifty day moving average is $10.29 and its two-hundred day moving average is $6.34.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The firm had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. Sell-side analysts predict that Alumis Inc. will post -8.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Guggenheim increased their price objective on Alumis from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Wells Fargo & Company raised their target price on Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, January 6th. Leerink Partners boosted their target price on shares of Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Finally, UBS Group reiterated an “outperform” rating on shares of Alumis in a report on Tuesday, January 6th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.67.

Institutional Trading of Alumis

Large investors have recently bought and sold shares of the company. Samsara Biocapital LLC increased its position in shares of Alumis by 47.0% in the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after buying an additional 1,534,872 shares in the last quarter. Foresite Capital Management VI LLC increased its holdings in Alumis by 1.1% during the 2nd quarter. Foresite Capital Management VI LLC now owns 4,247,670 shares of the company’s stock valued at $12,743,000 after acquiring an additional 45,000 shares in the last quarter. Vanguard Group Inc. raised its position in Alumis by 18.4% during the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after acquiring an additional 625,404 shares during the last quarter. Trium Capital LLP raised its position in Alumis by 17.9% during the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock worth $12,457,000 after acquiring an additional 474,072 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in shares of Alumis in the second quarter valued at about $5,779,000.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Director Srinivas Akkaraju purchased 588,235 shares at $17.00 (~$10.0M), increasing his stake by ~46% — a material insider buy that signals management confidence. Read More.
• Positive Sentiment: Director James B. Tananbaum (and affiliated Foresite entities) bought 411,764 shares at $17.00 (~$7.0M), lifting their holdings materially — institutional/insider demand typically boosts sentiment and liquidity. Read More.
• Positive Sentiment: Major shareholder Foresite Labs/Capital increased its position (411,764 shares at $17), reinforcing institutional support and amplifying the buying pressure. Read More.
• Positive Sentiment: Market headlines cite positive plaque‑psoriasis data for lead candidate Envudeucitinib — the clinical update is a direct fundamental catalyst behind the rapid run‑up in the stock. Read More.
• Positive Sentiment: An analyst price‑target lift was reported (79.14% increase to $36.28), reflecting the same bullish re‑rating driving buy‑side interest. Read More.
• Neutral Sentiment: Several firms have reissued “outperform/buy” ratings and higher targets (MarketBeat/coverage roundup); broader analyst coverage likely magnifies volatility but also improves liquidity. Read More.
• Neutral Sentiment: Institutional ownership changes (historic buys by multiple funds) mean the stock can see larger block trades and volume swings; that can support rallies but also increases headline sensitivity. Read More.
• Negative Sentiment: Fundamental risk remains: Alumis missed most recent quarterly EPS and revenue estimates and is loss‑making — clinical execution or disappointing future readouts could quickly reverse gains. Read More.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.